This hypothesis is supported by preclinical trial findings that showed that enhancement of ACE2 activity in a mouse model of Alzheimer's disease caused a striking reversal of cognitive decline and approximately halved the levels of anticipated Aβ pathology.7 Here, ACE2 is linked to Alzheimer disease.